Kinases (Tyrosine Specific Protein)
Tyrosine specific kinases form a large family of enzymes that are responsible for catalyzing the transfer of ATP to specific tyrosine residues in target proteins. In turn, the phosphorylation of tyrosine residues causes a change in the function of the protein that they are contained in. They function in a variety of processes, signal transduction pathways, and actions, and may be responsible for key events in the body[1]. Axon Ligands™ that interact with tyrosine specific enzymes that are part of the JAK/STAT signaling pathway have been categorized independently. The remainder of Axon Ligands™ that lack interactions with tyrosine kinases of this particular signaling pathway are listed here, grouped on the basis of their selectivity.
[1] Receptor tyrosine kinase signaling: a view from quantitative proteomics. J. Dengjel,I. Kratchmarova, B. Blagoev. Mol. Biosyst. 2009, 5, 1112-1121.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3759 | (aR)-RP-6306 | (aR)-enantiomer of RP-6306 (Axon 3668); PKMYT1 inhibitor | Recently added | €180.00 |
| 1892 | 1-NM-PP1 | Potent tyrosine kinase inhibitor (TKI) of multiple targets (Src, Fyn, Abl, CDK, Trk) | €95.00 | |
| 1698 | A 770041 | Orally active src-family selective lck inhibitor | €140.00 | |
| 1378 | AG 490 | JAK2 inhibitor | €65.00 | |
| 2031 | AIM 100 | Specific inhibitor of Ack1 tyrosine kinase (also known as TNK2) | €95.00 | |
| 2005 | ASP 3026 | Inhibitor of the oncogenic fusion kinase EML4-ALK | €80.00 | |
| 2219 | AT 9283 | Multitargeted kinase inhibitor (Aurora A/B, JAK2/3, and BCR-Abl) | €85.00 | |
| 2226 | AVL 292 | Potent, selective, covalent BTK inhibitor | €110.00 | |
| 1778 | AZ 960 | JAK2 inhibitor | €95.00 | |
| 1456 | AZD0530 difumarate | Inhibitor of SRC and ABL tyrosine kinases | €70.00 | |
| 1955 | Baricitinib | Inhibitor of JAK1 and JAK2 | €70.00 | |
| 3813 | BMS-911543 | Potent, selective and orally active inhibitor of JAK2 | Recently added | Inquire |
| 2978 | Brigatinib | Potent, selective, and orally active anaplastic lymphoma kinase (ALK) inhibitor | €80.00 | |
| 3671 | CEP-33779 | Potent, selective and orally bioavailable JAK2 inhibitor | €95.00 | |
| 2775 | Cerdulatinib | Orally active dual Syk/JAK inhibitor | €85.00 | |
| 2018 | CGI 1746 | Inhibitor of Bruton's tyrosine kinase (BTK) | €50.00 | |
| 2097 | CGP 77675 | Src Family kinase (SFK) inhibitor | €65.00 | |
| 1338 | CP 690550 | JAK3 inhibitor | €60.00 | |
| 2992 | CTx-0294885 | Broad-spectrum kinase inhibitor | €90.00 | |
| 1681 | CYT 387 | JAK1 and JAK2 inhibitor | €90.00 | |
| 1392 | Dasatinib | Bcr-Abl and Src tyrosine kinase inhibitor | €90.00 | |
| 2574 | Defactinib | Orally available second generation inhibitor of FAK and PYK2 | €80.00 | |
| 3717 | GSK2256098 | FAK inhibitor | Inquire | |
| 2121 | INNO 406 | Dual Bcr-Abl and Lyn kinase inhibitor | €85.00 | |
| 1843 | JAK2 inhibitor 13 | JAK2 inhibitor | €110.00 | |
| 2294 | KRCA 0008 | Potent and selective dual ALK/ACK1 inhibitor with good drug-like properties | €95.00 | |
| 2862 | LFM-A13 | Inhibitor of Bruton's tyrosine kinase (BTK) | €90.00 | |
| 3270 | Lj-1-60 | Fyn inhibitor targeting the Fyn/Stat3 pathway | €90.00 | |
| 2554 | LY 2784544 | Potent, selective and ATP-competitive inhibitor of mutated janus kinase 2 (JAK2V617F) | €95.00 | |
| 1494 | MK 1775 | Wee1 kinase inhibitor | €80.00 | |